PRIOR AUTHORIZATION REQUEST

Ustekinumab Products

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL** PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

1	Will the requested medication be used in combination with a biologic disease-modifying antirheumatic drug (DMARD) or targeted synthetic DMARD? [Note: Examples of biologics include but not limited to adalimumab SC products (Humira, biosimilars), Cimzia, etanercept SC products (Enbrel, biosimilars), infliximab IV products (Remicade, biosimilars), Actemra (IV or SC), Simponi, Simponi Aria (IV or SC), Orencia (IV or SC), rituximab IV products (Rituxan, biosimilars), Kineret, Siliq, Cosentyx, Taltz, Ilumya, Skyrizi, Tremfya, Entyvio. Examples of targeted synthetic DMARD include but not limited to Otezla, Olumiant, Rinvoq, or Xeljanz/XR.]	Yes	No

PRIOR AUTHORIZATION REQUEST

[If yes, no further questions.]

2 What is the requested medication formulation?
[] INTRAVENOUS (If checked, go to 24)

[] SUBCUTANEOUS (If checked, go to 3)

3 Is the request for a formulary Ustekinumab product (Pyzchiva, Steqeyma, Yesintek)? Yes No
[If yes, skip to question 5.]

4 Does the patient have documented intolerance or failed treatment for at least 3 months with preferred Ustekinumab product(s) (Pyzchiva, Steqeyma, Yesintek)? Yes No
[If no, no further questions.]

5 Is the patient currently receiving the requested medication? Yes No
[If no, skip to question 10.]

6 Has the patient been receiving medication samples for the requested medication? Yes No
[If yes, skip to question 10.]

7 Does the patient have a previously approved PA on file with the current plan? Yes No
[Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.]
[If no, skip to question 9.]

8 Has the patient been established on therapy for at least 3 months? Yes No
[If yes, skip to question 39.]
[If no, skip to question 11.]

9 Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. Yes No
[If yes, skip to question 11.]
[If no, no further questions.]

10 What is the indication or diagnosis?
[] Plaque Psoriasis (If checked, go to 12)

[] Psoriatic Arthritis (If checked, go to 18)

[] Crohn's Disease [Note: Includes adults with fistulizing Crohn's disease or Crohn's disease of the ileal pouch.] (If checked, no further questions)

[] Ulcerative Colitis (If checked, no further questions)

[] Ankylosing Spondylitis (If checked, no further questions)

PRIOR AUTHORIZATION REQUEST

[] Other (If checked, no further questions)

11 What is the indication or diagnosis?
[] Plaque Psoriasis (If checked, go to 12)

[] Psoriatic Arthritis (If checked, go to 18)

[] Crohn's Disease [Note: Includes adults with fistulizing Crohn's disease or Crohn's disease of the ileal pouch.] (If checked, go to 28)

[] Ulcerative Colitis (If checked, go to 33)

[] Ankylosing Spondylitis (If checked, no further questions)

[] Other (If checked, no further questions)

12	Is the patient greater than or equal to 6 years of age? [If no, no further questions.]	Yes	No
13	Is the requested medication being prescribed by or in consultation with a dermatologist? [If no, no further questions.]	Yes	No
14	Has the patient tried at least TWO traditional systemic agents for psoriasis for at least 3 months such as methotrexate, cyclosporine, or acitretin? [If yes, skip to question 16.]	Yes	No
15	Has the patient experienced an intolerance to at least TWO traditional systemic agents for psoriasis such as methotrexate, cyclosporine, or acitretin? [If no, no further questions.]	Yes	No
16	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitors Enbrel (etanercept) and an adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
17	Does the dose of the requested medication exceed the FDA approved label dosing for the indication? (Dosing weight less than 60 kg: 0.75 mg/kg at weeks 0, 4 and then every 12 weeks thereafter. Dosing weight 60 kg to 100 kg: 45 mg at weeks 0, 4 and then every 12 weeks thereafter. Dosing weight greater than 100 kg: 90 mg at weeks 0, 4 and then every 12 weeks thereafter). [No further questions.]	Yes	No
18	Is the patient greater than or equal to 6 years of age? [If no, no further questions.]	Yes	No

PRIOR AUTHORIZATION REQUEST

19	Has the patient tried TWO conventional synthetic disease-modifying antirheumatic drugs (DMARD) for at least 3 months such as methotrexate (oral or injectable), leflunomide, hydroxychloroquine and/or sulfasalazine? [If yes, skip to question 21.]	Yes	No
20	Has the patient experienced an intolerance to at least TWO conventional synthetic disease-modifying antirheumatic drug (DMARD) such as methotrexate (oral or injectable), leflunomide, hydroxychloroquine and/or sulfasalazine? [If no, no further questions.]	Yes	No
21	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitors Enbrel (etanercept) and an adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab- adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
22	Has documentation been submitted to confirm that the patient has an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
23	Does the dose of the requested medication exceed the FDA approved label dosing for the indication? (Dosing weight less than 60 kg: 0.75 mg/kg at weeks 0, 4 and then every 12 weeks thereafter. Dosing weight 60 kg to 100 kg: 45 mg at weeks 0, 4 and then every 12 weeks thereafter. Dosing weight greater than 100 kg: 90 mg at weeks 0, 4 and then every 12 weeks thereafter). [No further questions.]	Yes	No
24	Is the request for a formulary Ustekinumab product (Pyzchiva, Steqeyma, Yesintek)? [If yes, skip to question 26.]	Yes	No
25	Does the patient have documented intolerance or failed treatment for a least 3 months with preferred Ustekinumab product(s) (Pyzchiva, Steqeyma, Yesintek)? [If no, no further questions.]	Yes	No
26	Will the requested medication be used as induction therapy? [If no, no further questions.]	Yes	No
27	What is the indication or diagnosis? [] Crohn's Disease [Note: Includes adults with fistulizing Crohn's disease or Crohn's disease of the ileal pouch.] (If checked, go to 28) [] Ulcerative Colitis (If checked, go to 33) [] Plaque Psoriasis (If checked, no further questions)		

PRIOR AUTHORIZATION REQUEST

[] Psoriatic Arthritis (If checked, no further questions)

[] Other (If checked, no further questions)

28	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
29	Is the patient currently taking or has tried a systemic corticosteroid? [If yes, skip to question 31.]	Yes	No
30	Is systemic corticosteroid contraindicated for the patient? [If no, no further questions.]	Yes	No
31	Has the patient tried TWO other conventional systemic therapies for Crohn's disease or was intolerant to other conventional systemic therapies? [Note: Examples of other agents for Crohn's disease include azathioprine, 6-mercaptopurine, or methotrexate.] [If no, no further questions.]	Yes	No
32	Has documentation been submitted to confirm that the patient has had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitor an adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab-adbm)? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 37.] [If no, no further questions.]	Yes	No
33	Is the patient greater than or equal to 18 years of age? [If no, no further questions.]	Yes	No
34	Has the patient had a trial of TWO systemic agents for ulcerative colitis or was intolerant to systemic agent? [Note: Examples include 6-mercaptopurine, azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone or methylprednisolone.] [If no, no further questions.]	Yes	No
35	Has documentation been submitted to confirm that the patient has had an intolerance, contraindication to, or failed treatment for at least 3 months with preferred TNF inhibitor an adalimumab product (Hadlima, Simlandi, Yusimry, or adalimumab-adbm)? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
36	Has documentation been provided to confirm that the patient has had an intolerance, contraindication to, or failed treatment for at least 3 months with Xeljanz (tofacitinib), following treatment failure with adalimumab? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No

PRIOR AUTHORIZATION REQUEST

37	Does the dose exceed FDA approved label dosing for the indication? (Dosing weight less than 55 kg: 260 mg. Dosing weight 55 to 85 kg: 390 mg. Dosing weight greater than 85 kg: 520 mg). [If yes, no further questions.]	Yes	No
38	Is the requested medication being prescribed by or in consultation with a gastroenterologist? [No further questions.]	Yes	No
39	What is the indication or diagnosis? [] Crohn's Disease [Note: Includes adults with fistulizing Crohn's disease or Crohn's disease of the ileal pouch.] (If checked, go to 40) [] Plaque Psoriasis (If checked, go to 41) [] Psoriatic Arthritis (If checked, go to 42) [] Ulcerative Colitis (If checked, go to 43) [] Ankylosing Spondylitis (If checked, no further questions) [] Other (If checked, no further questions)		
40	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of a response to therapy include a decrease in symptoms such as diarrhea, pain, and/or bleeding; and/or improvement in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood count (CBC), and/or fecal calprotectin (fCal). The patient may not have a full response, but there should have been a recent or past response to Stelara.] [No further questions.]	Yes	No
41	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: The patient may not have a full response, but there should have been a recent or past response to Stelara.] [No further questions.]	Yes	No
42	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of a response to therapy include less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improvements in acute phase reactants (for example, C-reactive protein). The patient may not have a full response, but there should have been a recent or past response to Stelara.]	Yes	No

PRIOR AUTHORIZATION REQUEST

	[No further questions.]		
43	Has documentation been submitted to confirm that the patient has experienced a clinically significant response, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [Note: Examples of a response to therapy include decreased stool frequency or rectal bleeding.]	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.